How will the novel CFTR-function restoring therapies impact the CF landscape?
The arrival of Vertex’s Kalydeco and Orkambi was a major advance in the disease-modifying CF therapy. However, despite their comparative success, patients’ progress and demand persists for improved modalities that can restore the CFTR function in all CF genotypes. Vertex’s tezacaftor + ivacaftor and Galapagos NV/AbbVie’s GLPG 1837 form part of a rich pipeline, but which candidates stand out to key opinion leaders (KOLs)? Which products and combinations are likely to succeed? And will they improve survival and help patients live beyond their current life expectancy of ~40 years?
Learn how KOLs see the CF market evolving in KOL Insight: Cystic Fibrosis (CF).
12 US and European KOLs provide candid insights on 4 marketed and 11 emerging therapies targeting CFTR function and symptomatic aspects of the CF disease.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“It is very rare that you see a treatment in any condition, particularly in respiratory medicine, where there is a very clear ‘treatment makes you better, stopping it makes you worse’. You know, utterly transformative in the way that ivacaftor was for those patients.”
EU Key Opinion Leader
KOLs from North America
KOLs from Europe
Plus 6 more - download the full list now >
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.